相关实验视频

Updated: Sep 17, 2025

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

尤科米亚乌尔莫伊德 (Eucommia ulmoides) 种子油是抑制消化系统瘤的补充食品

Jinzheng Wu¹, Liang Wen¹, Durairaj Karthick Rajan²

¹Department of Anesthesiology, The Second XiangYa Hospital, Central South University, Changsha, China.

Frontiers in pharmacology

|July 3, 2025

概括

乌克米亚乌尔莫伊德 (Eucommia ulmoides) 种子油 (EUSO) 有效地抑制了消化系统癌症 (如肝癌和胰腺癌) 的生长和传播. 通过准PI3K-AKT-mTOR通路,EUSO的工作显示出作为补充癌症治疗的希望.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
自然产品化学化学

背景情况:

自然产品对于抗癌药物发现至关重要.
乌克米亚乌尔莫伊德 (Eucommia ulmoides) 种子油 (EUSO) 显示出对抗代谢障碍的潜力.
欧苏的抗癌作用,特别是对消化系统癌症,在很大程度上是未被探索的.

研究的目的:

研究EUSO对消化系统癌症的抗瘤作用.
阐明EUSO行动的基础分子机制.
评估EUSO作为辅助癌症治疗的潜力.

主要方法:

在体外测试 (CCK-8,殖民地形成,Transwell,流细胞计) 用于肝脏和胰腺癌细胞.
在体内,使用裸体小鼠的皮下异种移植模型评估了抗瘤疗效.
转录基因分析 (RNA-seq) 和西方抹杀确定了EUSO监管的信号通路.

主要成果:

欧苏体验表明了对癌细胞增殖,殖民地形成和迁移的剂量依赖抑制.
在癌细胞中,EUSO诱导了亡,并在体内抑制了瘤的生长.
发现EUSO通过减少AKT和mTOR酸化来降低PI3K-AKT-mTOR通路的下调.

结论:

通过抑制PI3K-AKT-mTOR通路,EUSO减轻了消化系统癌症的进展.
EUSO显示出作为癌症管理的辅助治疗剂的潜力.
需要进一步的临床研究来探索EUSO的化学预防和补充治疗价值.

关键词:

欧盟驻外工作人员 (EUSO) 在通过PI3K-Akt信号通路传递信号.补充食品是一种补充食品.消化系统的消化系统.尤科米亚乌尔莫伊德 (eucommia ulmoides) 种子油的种子油.

更多相关视频

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

Rapid Model to Evaluate the Anti-Obesity Potential of a Combination of Syzygium aromaticum Clove and Cuminun cyminum Cumin on C57BL6/j Mice Fed High-Fat Diet

Rapid Model to Evaluate the Anti-Obesity Potential of a Combination of Syzygium aromaticum Clove and Cuminun cyminum Cumin on C57BL6/j Mice Fed High-Fat Diet

Published on: July 31, 2021

相关概念视频

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...

Drugs for Treatment of Constipation-Predominant IBS

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...